



Supernus Pharmaceuticals, Inc.  
Investor Relations Department  
1550 East Gude Drive  
Rockville, MD 20850  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: SUPN**

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 39.40                      |
| Trade Time:   | 4:00 PM ET<br>Feb 23, 2018 |
| Change:       | 0.95  (+2.471%)            |
| Day Range     | 38.15 - 39.70              |
| 52-Week Range | 24.92 - 50.05              |
| Volume        | 291,143                    |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Supernus Pharmaceuticals extensive expertise in product development has been built over the past 20 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, upon our acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals.

... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

*Feb 12, 2018*

[Supernus to Host Fourth Quarter and Full Year 2017 Earnings Conference Call](#)

*Jan 12, 2018*

[Supernus Mourns the Loss of Board Member William Nuerge](#)

*Jan 2, 2018*

[Supernus to Present at the 2018 J.P. Morgan Healthcare Conference](#)

*Nov 8, 2017*

[Supernus to Present at Three November Healthcare Conferences](#)

*Nov 6, 2017*

[Supernus Announces Third Quarter 2017 Financial Results](#)

## Upcoming Events [\[ View all \]](#)

*Feb 28, 2018 9:00 AM ET*

[Supernus Pharmaceuticals 4Q 2017 Earnings Conference Call](#)

## Financials & Filings [\[ View all \]](#)

[Fourth Quarter Financial Results](#)

*Mar 16, 2017*

[Annual Report \(10-K\)](#)

*Apr 27, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Nov 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 3, 2017*

[Quarterly Report \(10-Q\)](#)

*May 9, 2017*

[Quarterly Report \(10-Q\)](#)